Ipamorelin vs Sermorelin: Two Doors Into the Same Axis

Sermorelin is GHRH(1-29), the shortest fragment of growth-hormone-releasing hormone that retains the parent hormone's activity. GHRH itself was characterised in the early 1980s from a pancreatic tumour that had caused acromegaly,[3] and sermorelin acts where the hormone does: at the GHRH receptor on the pituitary somatotroph, providing the hypothalamic release signal.

Ipamorelin is a synthetic pentapeptide, Aib-His-D-2-Nal-D-Phe-Lys-NH2, and it does not touch the GHRH receptor at all. It is an agonist at the ghrelin receptor, the growth-hormone secretagogue arm of the same axis. Its original characterisation is explicit about what made it notable: it released growth hormone with minimal effect on ACTH, cortisol and prolactin, which distinguished it from the earlier secretagogues.[1]

The two receptors are synergistic in the physiology. GHRH provides the release signal; ghrelin-receptor agonism amplifies the response to it. That is the reason axis research so often pairs a GHRH analogue with a secretagogue instead of choosing, and the reason the combined stimulation exceeds either alone in the classic studies.

Amino Acid Sequence

Amino Acid Sequence

Sermorelin is unusual in this catalogue for having a genuine pharmaceutical history. It was developed and approved for paediatric growth-hormone deficiency, reviewed as a drug in the clinical literature,[2] and later withdrawn from the market for commercial reasons rather than on a safety finding.[4] That gives it a body of human pharmacology that almost nothing else here can claim.

Ipamorelin has original developer pharmacology of good quality, including the selectivity work that defines it[1] and follow-on studies on bone and body composition in animal models,[5][6] but it never completed a development programme and has no approval anywhere.

Neither compound's reputation in forums is evidence, and the distance between that reputation and the published record is larger for ipamorelin than for sermorelin.

• ·Selectivity. Ipamorelin's defining published property is a growth-hormone response without the ACTH, cortisol and prolactin signal that accompanied earlier secretagogues.[1] Sermorelin acts upstream at the GHRH receptor and does not raise the same question.
• ·Sequence complexity. Ipamorelin is a five-residue sequence carrying a non-standard residue, two D-form amino acids and C-terminal amidation. That is a lot of engineering in a small molecule, and it is all visible in the notation and in the mass. Sermorelin is a 29-residue straight fragment, a longer but more conventional synthesis.
• ·Anti-doping. Both classes appear on the World Anti-Doping Agency Prohibited List. Growth-hormone secretagogues and GHRH analogues are both covered, which is relevant to anyone working around tested sport.
• ·Regulatory position. Neither is an authorised health product in Canada. Sermorelin's historic approval was in another jurisdiction and it is no longer marketed; that history does not make the research material an approved product.

The three-figure standard applies to both: mass-spectrometric identity against the theoretical mass, HPLC purity, and measured content against the labelled amount. For ipamorelin the identity line does slightly more work than usual, because the amidated terminus and the two D-form residues all shift the mass, and a synthesis that dropped any of them would still look clean on a purity chromatogram.

Certificates for both are published per lot before sale and carry a key that resolves on the testing laboratory's own database. The mechanics are in how to verify a peptide COA.

Published Certificate

Batch

IPAM-CA-26G-10

Purity (HPLC)

99.753%

Measured content

11.75 mglabelled 10 mg

Laboratory

Janoshik

Verify on the lab’s own databaseAll published certificates

Published Certificate

Batch

SERM-CA-26D-01

Purity (HPLC)

98.78%

Measured content

5.56labelled 5 mg

Laboratory

Testides

Verify on the lab’s own databaseAll published certificates

If the research question is about the release signal itself, sermorelin is the compound that provides it and the one with the human pharmacology behind it. If the question is about secretagogue selectivity, ipamorelin is the compound the selectivity literature is actually about. If the question is about the axis as a system, the published designs generally use both, because that is how the physiology works.

Both are stocked with their own lot certificates.

Available at Eppix Labs

Buy Ipamorelin Canada | GH Secretagogue 10mg

10mg

Every batch tested by an independent laboratory, with the certificate published before sale.

From $60.00 CADIn stock

Available at Eppix Labs

Buy Sermorelin Canada | GHRH 5mg

5mg

Every batch tested by an independent laboratory, with the certificate published before sale.

From $50.00 CADIn stock